MINI FUTURE SHORT - JAZZ PHARMACEUTICALS Share Price

Certificat

DE000MB3TT01

Market Closed - Börse Stuttgart 17:51:37 20/06/2024 BST
5.55 EUR +9.90% Intraday chart for MINI FUTURE SHORT - JAZZ PHARMACEUTICALS
Current month-12.17%
1 month-7.85%
Date Price Change
20/06/24 5.55 +9.90%
19/06/24 5.05 -0.20%
18/06/24 5.06 -1.17%
17/06/24 5.12 -1.73%
14/06/24 5.21 +0.19%

Delayed Quote Börse Stuttgart

Last update June 20, 2024 at 05:51 pm

More quotes

Static data

Product typeKnock-Out mit Stop Loss
Buy / SellPUT
Underlying JAZZ PHARMACEUTICALS PLC
Issuer Morgan Stanley
WKN MB3TT0
ISINDE000MB3TT01
Date issued 20/02/2023
Strike 168.2 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.91
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 6
Lowest since issue 1.73

Company Profile

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Sector
-
More about the company

Ratings for Jazz Pharmaceuticals plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Jazz Pharmaceuticals plc

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
112.7 USD
Average target price
179.6 USD
Spread / Average Target
+59.42%
Consensus